Tranylcypromine

Tranylcypromine is a classic antidepressant belonging to the monoamine oxidase inhibitor family, acting as an irreversible and nonselective inhibitor of both the A and B forms of the enzyme monoamine oxidase ^[1]. Chemically it is a phenylcyclopropylamine and can be viewed as derived from amphetamine by closing its side chain into a cyclopropane ring, a kinship that gives the drug mild stimulant-like qualities ^[1]. It sits alongside phenelzine and isocarboxazid among the older, irreversible MAOIs ^[3].

The drug is used chiefly for major depressive disorder, and it is valued particularly in treatment-resistant depression and in atypical depression, where controlled trials and a meta-analysis have confirmed it to be effective and, in the right hands, safe ^[2]. Because its effects build over several weeks and it carries important dietary and drug restrictions, current guidelines generally place it as a later-line option after other antidepressants have failed ^[2]. Tranylcypromine was introduced around 1960 and approved in the United States in 1961; it was briefly withdrawn in 1964 after deaths from hypertensive crises, then reintroduced with clear warnings ^[1]. It is prescription-only, marketed under the brand name Parnate among others, and taken by mouth as tablets.

The best-known hazards of tranylcypromine stem from its powerful, lasting inhibition of monoamine oxidase ^[1]. Foods rich in the amine tyramine, such as aged cheeses, cured meats, and various fermented products, can trigger a sharp and potentially dangerous rise in blood pressure, so a tyramine-restricted diet is required throughout treatment and for a period after stopping ^[1][3]. Combining it with drugs that raise serotonin, including SSRIs, SNRIs, tramadol, and MDMA, can cause serotonin toxicity, and combining it with indirect stimulants can provoke a hypertensive crisis ^[1][3]. Common side effects include dizziness from low blood pressure on standing, insomnia, and, unlike many antidepressants, a tendency toward weight loss rather than gain ^[1].

This is the one with the famous rules. Because MAO-A is knocked out in the gut too, tyramine-rich foods (aged cheese, cured meats, some fermented items) can trigger a hypertensive crisis, a dangerous blood pressure spike. Combining it with serotonergic drugs (SSRIs, SNRIs, tramadol, many others) risks serotonin syndrome, and you need washout periods on both sides. It is genuinely effective but demands respect and medical supervision. Prescription only.

Tranylcypromine causes hypertensive emergencies when combined with sympathomimetics and serotonergic compounds. Amphetamine, methamphetamine, dextroamphetamine, and cocaine produce hypertensive urgency or emergency; this is a pharmacodynamic interaction in which the MAOI's blockade of monoamine catabolism allows these releasers to cause massive norepinephrine accumulation ^[4]. Serotonin toxicity has been documented with dextromethorphan, tramadol, meperidine, methadone, and MDMA; these are pharmacodynamic interactions resulting from serotonin pathway over-activation ^[4].

A case documented hypertensive emergency following psilocybin mushroom use in a patient on tranylcypromine and dextroamphetamine-amphetamine, likely via phenylethylamine (a trace component) acting as a substrate for the blocked monoamine oxidase ^[6]. Armodafinil with tranylcypromine has produced acute hypertensive crises in multiple documented cases ^[7]. Esketamine showed clinically insignificant blood pressure changes despite statistical significance ^[8]. Many common medications and herbal supplements have never been systematically studied in combination with tranylcypromine.

Checking a whole stack? Run it through interactions + stacks.

Tranylcypromine was developed by the pharmaceutical company Smith, Kline and French and introduced around 1960 as one of the early monoamine oxidase inhibitors for depression. Chemically it is distinctive, being a cyclopropylamine structurally related to amphetamine, a kinship that gives it mild stimulant character alongside its enzyme-inhibiting action.

Its history includes a notable setback: in 1964 it was briefly withdrawn from the United States market after reports of severe, sometimes fatal hypertensive reactions, before being reintroduced with strengthened warnings and clear guidance on avoiding tyramine-rich foods and interacting drugs. Over the following decades it settled into a defined role, valued particularly for depression that had failed to respond to newer agents. Sold under the brand name Parnate, it remains in use today as a potent option for treatment-resistant depression, prescribed by clinicians experienced in managing its dietary and drug interactions.

Tranylcypromine occupies a respected niche as a powerful antidepressant that can succeed where many others have failed, and specialists in mood disorders often regard the older MAOIs as underused rather than obsolete. Its irreversible, non-selective blockade of monoamine oxidase produces broad increases in serotonin, norepinephrine, and dopamine, and its mild amphetamine-like character can lend a helpful activating quality for some patients with severe or atypical depression.

Enthusiasts note that, in capable hands and with proper dietary care, it can deliver striking relief in otherwise intractable cases. That reputation is inseparable from a candid appreciation of its demands: patients must restrict tyramine-rich foods to avoid blood-pressure spikes, and combinations with serotonergic drugs must be avoided to prevent serotonin toxicity. For the right person, working with an experienced prescriber, it remains a genuinely valuable and sometimes uniquely effective treatment.